Europe Organ Preservation Market Size, Share, and Industry Trends Forecast 2026-2036
Europe Organ Preservation Market Intelligence
Asset-light leasing models for machine perfusion devices is tilting competitive dynamics toward firms that can bundle service contracts with hardware deployment. XVIVO Perfusion leverages its installed base of ex-vivo organ support platforms across Nordic transplant networks. Paragonix Technologies anchors its position through proprietary cold-chain transport containers that extend viable ischemia windows for cardiac allografts. Dr. Franz Koehler Chemie GmbH competes via specialized preservation solution formulations that sustain cellular metabolism during static cold storage.
Europe organ preservation encompasses technologies and consumables that maintain graft viability between procurement and transplantation, typically involving temperature-modulated storage media, perfusion circuits with oxygen carriers, and pH-buffered electrolyte solutions designed to prevent ischemia-reperfusion injury. Static storage solutions occupy the largest volume share due to low per-procedure cost and established clinical familiarity, though machine perfusion represents the fastest-expanding margin pool as transplant programs seek to recover marginal organs. Research institutions and biobanks constitute a concentrated demand node for cryopreservation technology where biopreservation protocols enable long-term tissue banking for future regenerative applications.
EMA's Good Manufacturing Practice standards for organ transport devices and the EU Tissues and Cells Directive shape product registration pathways and post-market surveillance obligations across member states. CE marking under the EU Medical Device Regulation governs machine perfusion system commercialization, while national health technology assessment bodies in France and Germany determine reimbursement eligibility for novel preservation modalities. Stakeholders must monitor how evolving MDR classification rules for combination device-drug products will reshape regulatory timelines for integrated perfusion solutions.

Market Dynamics
Machine perfusion systems are compressing procurement cycles for transplant centers as EMA's MDR classification rules force hardware vendors to bundle drug-device combinations under stricter conformity assessment pathways.
Growth Catalysts
- EU Tissues and Cells Directive harmonization:Cross-border organ exchange protocols are standardizing quality benchmarks for preservation solutions across member states.
- Normothermic liver perfusion:University hospitals in Germany are anchoring regional networks that extend viable ischemia windows for marginal grafts.
- France:ANSM's accelerated assessment pathways for breakthrough medical devices are shortening time-to-reimbursement for novel perfusion platforms.
Market Restraints
- Single-source oxygen carrier supply:Perfusion circuits depend on proprietary hemoglobin-based oxygen carriers manufactured by concentrated European biotech suppliers.
- MDR transition costs:Small device manufacturers face capital intensity for clinical evidence generation required under EU Medical Device Regulation recertification.
- Static cold storage persistence:Established low-cost protocols for kidney allografts limit penetration of capital-intensive machine perfusion in cost-constrained programs.
Strategic Opportunities
- Spain:Underdeveloped machine perfusion infrastructure creates whitespace for leasing-based service models in high-volume transplant coordination centers.
- Cryopreservation for biobanking:Research institutions are expanding long-term tissue banking protocols for regenerative medicine applications.
- Integrated device-drug combinations:EMA's evolving guidance on combination products creates first-mover advantage for firms with in-house formulation capabilities.
Industry Challenges
- Perfusionist training pipelines:Specialized clinical engineering expertise for ex-vivo organ support systems remains concentrated in Nordic and German academic centers.
- CE marking timeline compression:Notified body capacity constraints under MDR are extending conformity assessment durations for novel transport container designs.
Report Scope
MarkWide Research| Attributes | Details |
|---|---|
| Report Title | Europe Organ Preservation Market |
| Market Size in 2026 | $87.5 Million |
| Market Size in 2035 | $158.18 Million |
| CAGR (2026 – 2036) | 6.8% |
| Historical Year | 2020-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2036 |
| Segmentation | Product Type: Static Storage, Dynamic Preservation, Machine Perfusion, Preservation Solutions End User: Hospitals, Transplant Centers, Research Institutions, Biobanks Application: Organ Transplantation, Research & Development, Organ Banking, Clinical Trials Technology: Hypothermic Preservation, Normothermic Preservation, Cryopreservation, Biopreservation |
| Companies Covered | OrganOx Limited, XVIVO Perfusion, Paragonix Technologies, Dr. Franz Koehler Chemie GmbH, Bridge to Life Ltd, TransMedics, Intas Pharmaceuticals (Accord Healthcare), Getinge AB, Terumo Corporation, Others |
| Regions Covered | Europe: Germany, Italy, France, UK, Spain, Denmark, Sweden, Austria, Belgium, Finland, Turkey, Poland, Russia, Greece, Switzerland, Netherlands, Norway, Portugal, Rest of Europe |
Get the full picture before you read further.
Download a free sample with table of contents, companies, segments, and methodology.
Europe Organ Preservation Market Strategic Shifts & Innovations
Preservation technology is bifurcating between premium dynamic perfusion platforms and refined static solutions, with regulatory pressure on transport container standards accelerating hardware refresh cycles.
Hypothermic machine perfusion for kidneys is rendering obsolete conventional static cold storage in programs seeking to recover expanded-criteria donor organs. French and British transplant centers are adopting these systems at accelerating pace for marginal graft assessment. The technology is compressing discard rates while elevating capital intensity requirements for procurement organizations.
EMA's evolving Good Manufacturing Practice standards for organ transport devices are tightening post-market surveillance obligations for container manufacturers. Industrial consequence includes mandatory design history file documentation and periodic safety update reporting. Machine perfusion system vendors face the steepest compliance burden as combination product classification rules crystallize.
Leasing structures with embedded service contracts are displacing capital purchase models for high-cost perfusion hardware. Nordic transplant networks pioneered this shift; German university hospitals are now replicating the structure. The model transfers obsolescence risk to vendors while locking procurement into multi-year consumable commitments.
Europe Organ Preservation Market Segmentation
Preservation modality selection directly determines graft viability windows and procurement economics for transplant programs across Germany, France, and the United Kingdom. Segment boundaries in this market reflect tension between capital-intensive dynamic systems and established low-cost static protocols, with regulatory pressure on transport standards accelerating technology refresh cycles.
Product Type:
Cost tier stratification separates capital equipment from consumable formulations, with procurement patterns diverging sharply between cash-constrained public hospitals and research-funded academic centers.
- Static Storage:Cold-chain containers and insulated transport boxes with pH-buffered electrolyte solutions dominate procurement volume across French and British transplant networks. German university hospitals anchor regional procurement for upgraded container designs as EMA's Good Manufacturing Practice standards tighten documentation requirements.
- Machine Perfusion:Ex-vivo organ support platforms with integrated oxygen carriers and continuous perfusion circuits command premium positioning. Nordic transplant networks pioneered leasing-based deployment models now replicating across German procurement clusters seeking to recover marginal grafts.
- Dynamic Preservation:Portable perfusion devices for organ transport extend viable ischemia windows during ground and air ambulance transfer.
- Preservation Solutions:Proprietary electrolyte formulations and cellular metabolism sustainers manufactured by specialized European chemical suppliers.
Static Storage holds installed capacity. Machine Perfusion is rotating up the share rankings.
End User:
Customer type determines purchasing authority structure, with centralized procurement in national health systems contrasting against decentralized decision-making in private research foundations.
- Transplant Centers:High-volume organ procurement organizations in Germany coordinate regional machine perfusion networks. ANSM's accelerated assessment pathways in France are shortening reimbursement timelines for novel preservation platforms adopted by these centers.
- Research Institutions:Academic medical centers in the United Kingdom and Netherlands drive demand for cryopreservation technology. Biobanking protocols for regenerative medicine applications concentrate funding for long-term tissue storage infrastructure.
- Hospitals:General acute care facilities with occasional transplant activity rely on static cold storage protocols.
- Biobanks:Specialized tissue repositories require ultra-low temperature preservation systems for multi-decade storage horizons.
Transplant Centers concentrate procurement authority. Research Institutions are climbing the fastest as biobanking applications expand.
Application:
Application scope spans from immediate clinical deployment to longitudinal research protocols, with regulatory pathway complexity varying by intended use case.
- Organ Transplantation:Clinical graft preservation for immediate implantation procedures drives volume demand. German transplant coordination centers are expanding normothermic liver perfusion capacity as marginal graft recovery protocols mature.
- Organ Banking:Intermediate-term storage for scheduled transplant procedures creates demand for transportable perfusion systems. French and British programs are piloting extended preservation windows for logistical optimization.
- Research & Development:Preclinical validation of novel preservation formulations and device prototypes.
- Clinical Trials:Regulatory-compliant preservation for investigational product testing under EMA supervision.
Organ Transplantation anchors revenue concentration. Organ Banking is gaining share fastest as scheduled procedure logistics mature.
Technology:
Technology maturity curves separate established hypothermic protocols from emerging normothermic and cryogenic approaches, with clinical evidence requirements scaling with temperature modulation complexity.
- Hypothermic Preservation:Temperature reduction to 4°C with ice-based cooling and cold perfusion solutions remains the clinical standard for kidney allografts. Static cold storage persistence in cost-constrained programs limits displacement despite machine perfusion advances.
- Normothermic Preservation:Body-temperature perfusion with oxygenated blood analogs sustains cellular metabolism during transport. German university hospitals anchor regional networks deploying this technology for liver graft assessment and recovery.
- Cryopreservation:Ultra-low temperature vitrification for long-term tissue banking in research and regenerative medicine applications.
- Biopreservation:Engineered biological scaffolds and cryoprotectant formulations for cellular and tissue preservation.
Hypothermic Preservation maintains procedural dominance. Normothermic Preservation shows steepest expansion trajectory as marginal graft protocols proliferate.

Need this report tailored to your region?
Request specific countries, segments, or companies — tailored to your requirements.
Regional Outlook
University hospitals and transplant coordination centers concentrate procurement authority across European markets, with national reimbursement frameworks determining technology adoption velocity for machine perfusion platforms.
Germany
Bavarian and North Rhine-Westphalian university hospitals anchor regional procurement networks for normothermic liver preservation technology. The Federal Joint Committee (G-BA) evaluates novel perfusion modalities for statutory health insurance reimbursement, creating structured access pathways. Berlin-Brandenburg transplant coordination centers are expanding machine perfusion capacity to recover marginal grafts from expanded-criteria donors.
United Kingdom
NHS Blood and Transplant coordinates centralized procurement for hypothermic machine perfusion systems across English transplant centers. The Medicines and Healthcare products Regulatory Agency (MHRA) applies post-Brexit conformity assessment pathways for CE-marked preservation devices. Greater London and Manchester academic medical centers are piloting extended organ banking protocols for logistical optimization of scheduled procedures.
France
Parisian and Lyonnais transplant centers drive demand for portable perfusion devices under ANSM accelerated assessment pathways. The Haute Autorité de Santé determines reimbursement eligibility for breakthrough preservation technologies through rapid health technology assessment. Île-de-France procurement clusters are standardizing quality benchmarks for cross-border organ exchange under EU Tissues and Cells Directive harmonization.
Spain
Catalan and Madrid transplant coordination centers present whitespace for leasing-based service models in high-volume organ procurement organizations. The Spanish Agency for Medicines and Health Products (AEMPS) oversees CE marking compliance for imported perfusion hardware. Barcelona academic hospitals are expanding cryopreservation infrastructure for biobanking applications in regenerative medicine research.
Netherlands
Randstad region university medical centers concentrate demand for static storage solution upgrades as EMA Good Manufacturing Practice standards tighten documentation requirements. The Dutch Health and Youth Care Inspectorate (IGJ) enforces post-market surveillance obligations for transport container manufacturers. Eindhoven-area research institutions are developing biopreservation protocols for long-term tissue banking infrastructure.
Europe Organ Preservation Market Key Industry Players
Channel-controlling players compete with product-specialist players across fragmented procurement hierarchies. Transplant centers and national health systems concentrate purchasing power through centralized tendering, while academic medical centers maintain discretionary authority for research-funded acquisitions. Three archetypes dominate: integrated device-drug combination suppliers, standalone perfusion hardware vendors, and specialized chemical formulation producers. Strategic moves center on leasing structure innovation and service contract bundling to lock multi-year consumable commitments.
Among Nordic-origin platform developers, XVIVO Perfusion exemplifies the installed-base expansion archetype through leasing models across regional transplant networks. Paragonix Technologies occupies a position within cold-chain transport specialization, anchoring proprietary container design for cardiac allograft applications. Dr. Franz Koehler Chemie GmbH represents the formulation-centric archetype, with German chemical manufacturing heritage supporting preservation solution supply.
| Leading Market Players |
|---|
| OrganOx Limited |
| XVIVO Perfusion |
| Paragonix Technologies |
| Dr. Franz Koehler Chemie GmbH |
| Bridge to Life Ltd |
| TransMedics |
| Intas Pharmaceuticals (Accord Healthcare) |
| Getinge AB |
| Terumo Corporation |
| Others |
Cost & Logistics Intelligence
Undercapacity in Nordic machine perfusion device manufacturing is compressing lead times and elevating supplier pricing power across German procurement networks. This utilization squeeze feeds directly into leasing rate negotiations and consumable bundling structures that transplant coordination centers must absorb.
Pricing Analysis
Certification level (CE-MDR Class III vs. Class IIa) creates the primary spread between premium perfusion platforms and commodity transport containers. Three-tier pricing structure across premium, standard, and economy levels segments procurement: university hospitals pay premium rates for integrated device-drug combinations with full service contracts, while regional transplant centers select standard-tier hardware with limited support, and occasional-use facilities default to economy static storage solutions. Cost compression in the standard tier is intensifying because MDR recertification expenses are concentrating among smaller container manufacturers. General acute care hospitals with sporadic transplant activity exhibit highest price sensitivity; German university hospitals with research funding demonstrate lowest sensitivity due to reimbursement pass-through mechanisms.
Supply Chain Analysis
Single-source vulnerability for hemoglobin-based oxygen carriers manufactured in Denmark and Sweden dominates supply chain risk assessment for perfusion circuit assemblers. Component sourcing draws from German precision pump manufacturers, Dutch bioreactor fabricators, and Italian tubing suppliers. Proprietary electrolyte formulations from Dr. Franz Koehler Chemie GmbH and specialized German chemical houses anchor consumable supply. Tariff exposure between the United Kingdom and continental EU member states is reshaping post-Brexit procurement routing for CE-marked devices. Distribution runs through centralized tendering by national health technology assessment bodies in France and Germany, with Nordic transplant networks operating through cooperative purchasing consortia.

Get the full picture before you read further.
Download a free sample with table of contents, companies, segments, and methodology.
Analyst Recommendations
Machine perfusion penetration remains below capacity across Spanish and Italian transplant infrastructure, creating runway for leasing-model expansion before competitive saturation sets in. Normothermic liver preservation protocols are accelerating clinical validation timelines and opening procurement windows.
For Market Incumbents: Insulate installed-base positions by embedding multi-year consumable lock-ins within service contracts that transfer MDR compliance burden to vendor balance sheets. XVIVO Perfusion's Nordic leasing structure offers a template for replication. Deepen backward integration into oxygen carrier production to neutralize Danish-Swedish supply concentration risk. Prioritize CE-MDR Class III certification investment for integrated device-drug combinations ahead of EMA guidance crystallization. For New Entrants and Emerging Players: Spanish underpenetration in high-volume transplant coordination centers presents whitespace for asset-light leasing models without incumbent switching costs. Target Catalonian and Madrid procurement clusters with portable perfusion devices for ground and air ambulance transfer applications. Biobanking cryopreservation infrastructure in Barcelona academic hospitals offers a secondary entry vector with research-funded purchasing authority. Pursue ANSM accelerated assessment pathway positioning in France to compress time-to-reimbursement against German G-BA evaluation timelines. For Investors and Strategic Acquirers: Recurring-revenue conversion is highest among integrated device-drug combination suppliers with captive consumable streams. Five-to-ten-year viability favors firms with in-house formulation capabilities and MDR regulatory expertise rather than pure hardware vendors exposed to obsolescence risk. Acquisition target archetype: mid-cap European perfusion platform developers with established CE marking and leasing infrastructure in German or Nordic networks. Monitor EMA combination product classification guidance publication as inflection signal for integrated solution valuation premiums.| Strategic Initiative | Industry Significance |
|---|---|
| CE-MDR Class III Certification Investment | EMA's evolving combination product rules elevate regulatory moats for integrated perfusion-drug platforms. |
| Leasing Model with Embedded Service Contracts | Nordic transplant networks pioneered this structure; German university hospitals now replicate to transfer obsolescence risk. |
| Backward Integration into Oxygen Carriers | Proprietary hemoglobin-based supply from Danish-Swedish biotech creates single-source vulnerability for circuit assemblers. |
| ANSM Accelerated Assessment Pathway Positioning | French regulatory fast-track shortens reimbursement timelines versus German G-BA evaluation for novel preservation platforms. |
| Biobanking Cryopreservation Infrastructure Expansion | Barcelona and Eindhoven research institutions drive demand for long-term tissue banking in regenerative medicine applications. |
Research Approach
Cross-validation between primary interviews with transplant surgeons, biomedical engineers, and GPO contracts managers anchors the qualitative findings against secondary validation from EMA MDR guidance documents, CE marking databases, and national health technology assessment publications. Hospital procurement databases and GPO contract disclosures supply pricing and volume benchmarks. Bottom-up segmentation modeling triangulates against top-down market sizing from device manufacturer revenue disclosures and transplant registry activity data.
Calibration against historical adoption curves for hypothermic machine perfusion in kidney transplantation informs penetration assumptions for normothermic liver protocols across the projection horizon. Segmentation dimensions include preservation modality, end-user type, application scope, and temperature modulation technology. CAGRs derive from logistic diffusion modeling of clinical validation timelines and reimbursement pathway progression. Forecast inputs incorporate EMA MDR transition completion schedules and ANSM accelerated assessment pathway uptake rates.
The forecast holds incumbent behavior within observed patterns; aggressive moves by integrated device-drug combination suppliers or unexpected EMA classification rule shifts would shift outcomes. Continuous validation against operating reality is the recommended discipline.
Need Custom Data?
Can't find what you're looking for? Our analysts can build a custom report tailored to your exact requirements.
1,000+
Global Clients
150+
Countries Covered
65,000+
Reports Available
Frequently Asked Questions
Why Work With MWR
Trusted by 1,000+ businesses across 150+ countries for high-stakes market decisions.
Ready to access intelligence that moves business?
Browse Reports →Trusted by Global Leaders
From Fortune-level organizations to global SMEs, we provide intelligence for high-stakes decisions.
Multi-Language Support
Research available in French, German, Spanish, Chinese, and more.
ISO & IAF Certified
Globally aligned quality standards ensuring methodological discipline and data integrity.
Competitive Relevance
Free inclusion of 3–4 additional companies of your choice in every report.
Customized Insights
Tailored intelligence for market entry, niche expansion, or competitive benchmarking.
Post-Sale Assistance
Dedicated coordination to help interpret findings and address queries post-delivery.
Cutting-Edge Methods
Structured data collection, advanced analytics, and expert validation for reliable forecasts.
Value for Investment
Credible, structured intelligence at a cost that makes strategic sense.
What Our Clients Say
My team needed the real numbers on AI spending for our Reinvention Services work. MarkWide delivered. No fluff, just a clear look at where the money is actually going. It saved us about three weeks of guesswork.
Accenture
We recently leaned on MarkWide Research for a deep dive into the evolving snacking habits within Southeast Asia. Their report on the premium biscuit segment was exceptionally detailed, providing us with the specific consumer sentiment data we needed to refine our regional flavor strategy. It wasn't just a data dump; the cultural nuances they captured helped us avoid several localization pitfalls.
Mondelez
Director of Global Consumer Insights
For a recent engagement in the automotive sector, we needed rigorous, independent verification of EV battery recycling capacities. MWR delivered a report that made our work easier. Their ability to segment the competitive landscape by chemical composition and regional throughput was exactly the kind of 'hard-to-find' intel that our team was looking for.
BCG
We were looking for a report on Xcelerator ecosystem's potential and got in touch with MarkWide's team through one of my old colleagues who worked with them in the past. Their research team was incredibly polite and were always available for us which was important for my team as this was a custom project. Their methodology for tracking industrial IoT adoption gave our R&D heads the clarity needed to prioritize our next-gen sensor development.
Siemens
Head of Industrial Digitalization
During a recent M&A project, we needed a fast, reliable breakdown of the Fintech landscape in Southeast Asia. MarkWide came through with a report that was actually readable and focused on the metrics that matter. It saved my team a good week of primary research, which, given our timelines, was a massive win.
KPMG
Advisory Partner
We tapped MarkWide Research for a deep dive into the ESG reporting software market. At Deloitte, our clients expect us to have the most current insights, and this report didn't disappoint. It provided a breakdown of the competitive field that was far more detailed than what we were expecting.
Deloitte
Lead Consultant, Sustainability Services
For our semiconductor division at Samsung, the supply chain forecast from MarkWide was incredibly useful. It provided a realistic outlook on raw material availability that helped us refine our production timelines. No fluff, just the data we needed to make a tough call.
Samsung
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarkWide Research, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer. Their customer first approach and high value engagement model have given us great analysis and excellent value for money.
3M
I can share that it was a positive experience wherein MarkWide Research demonstrated flexibility to adapt to our needs and delivered an excellent report that fits all our requirements. Personally, I liked the timely follow up by the team and we will definitively reach out in case more research support is required.
VITO
Related Reports
Medical Devices
Polyethersulfone Dialyzer Market
Medical Devices
Cranial Clamps Market
Medical Devices
Treatment Pumps Market
Medical Devices
Artificial Eye Market
Medical Devices
Neurofeedback Systems Market
Medical Devices
Global Robotic Endoscopy Devices Market
Medical Devices
Specimen Retrieval Nets Market
Medical Devices
Canada General Surgical Devices Market
Medical Devices
Global Prefilled Auto Injectors Market
Medical Devices
Multi-Channel Infusion Pumps Market
Medical Devices
Global Hemorrhoid Treatment Devices Market
Medical Devices
Corneal Implants Market
Medical Devices
Global Wearable Pregnancy Devices Market
Medical Devices
IVF Time-Lapse Imaging Devices Market
Medical Devices
Sleep Apnea Implants Market
Medical Devices
Transportable Ventilator Market